Entrectinib, marketed as Rozlytrek, is a medication provided in capsule form, available in strengths of 100mg and 200mg. It is a targeted therapy used in the treatment of specific types of cancers with certain genetic alterations, particularly tumors harboring NTRK gene fusions or ROS1 gene mutations.
IMPOMED Healthcare is dedicated to providing access to entrectinib, highlighting their commitment to offering targeted therapy options for individuals battling cancers with these specific genetic alterations. By facilitating access to this medication, they aim to improve the care and treatment outcomes for affected patients.
Entrectinib functions by targeting and inhibiting the activity of abnormal proteins produced by the NTRK or ROS1 genes, which are involved in promoting cancer growth. By blocking these aberrant proteins, entrectinib works to slow down or inhibit the growth of cancer cells harboring these genetic alterations.
IMPOMED Healthcare's provision of access to entrectinib represents a significant advancement in personalized medicine for cancer treatment. This targeted therapy option offers hope for improved outcomes and tailored care for individuals diagnosed with cancers carrying NTRK gene fusions or ROS1 gene mutations. To know more visit us on: https://www.impomedhealthcare.com/p/entrectinib-capsules-3